Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Related Citations for PubMed (Select 24952653)

1.

Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality.

Irvin MR, Booth JN 3rd, Shimbo D, Lackland DT, Oparil S, Howard G, Safford MM, Muntner P, Calhoun DA.

J Am Soc Hypertens. 2014 Jun;8(6):405-13. doi: 10.1016/j.jash.2014.03.003. Epub 2014 Mar 15.

PMID:
24952653
2.

Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun DA, Pressel SL, Black HR, Kostis JB, Probstfield JL, Whelton PK, Rahman M; ALLHAT Collaborative Research Group.

Hypertension. 2014 Nov;64(5):1012-21. doi: 10.1161/HYPERTENSIONAHA.114.03850. Epub 2014 Aug 4.

PMID:
25259745
3.

Cardiovascular and mortality risk of apparent resistant hypertension in women with suspected myocardial ischemia: a report from the NHLBI-sponsored WISE Study.

Smith SM, Huo T, Delia Johnson B, Bittner V, Kelsey SF, Vido Thompson D, Noel Bairey Merz C, Pepine CJ, Cooper-Dehoff RM.

J Am Heart Assoc. 2014 Feb 28;3(1):e000660. doi: 10.1161/JAHA.113.000660.

4.

Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension.

Irvin MR, Shimbo D, Mann DM, Reynolds K, Krousel-Wood M, Limdi NA, Lackland DT, Calhoun DA, Oparil S, Muntner P.

J Clin Hypertens (Greenwich). 2012 Oct;14(10):694-700. doi: 10.1111/j.1751-7176.2012.00690.x. Epub 2012 Aug 3.

5.

Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) study.

Tanner RM, Calhoun DA, Bell EK, Bowling CB, GutiƩrrez OM, Irvin MR, Lackland DT, Oparil S, McClellan W, Warnock DG, Muntner P.

Am J Kidney Dis. 2014 May;63(5):781-8. doi: 10.1053/j.ajkd.2013.11.016. Epub 2014 Jan 1. Review.

PMID:
24388119
6.

Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network.

Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, Calhoun DA.

Hypertension. 2013 Oct;62(4):691-7. doi: 10.1161/HYPERTENSIONAHA.113.01448. Epub 2013 Aug 5.

7.

The contributions of unhealthy lifestyle factors to apparent resistant hypertension: findings from the Reasons for Geographic And Racial Differences in Stroke (REGARDS) study.

Shimbo D, Levitan EB, Booth JN 3rd, Calhoun DA, Judd SE, Lackland DT, Safford MM, Oparil S, Muntner P.

J Hypertens. 2013 Feb;31(2):370-6. doi: 10.1097/HJH.0b013e32835b6be7.

8.

Healthy lifestyle factors and risk of cardiovascular events and mortality in treatment-resistant hypertension: the Reasons for Geographic and Racial Differences in Stroke study.

Diaz KM, Booth JN 3rd, Calhoun DA, Irvin MR, Howard G, Safford MM, Muntner P, Shimbo D.

Hypertension. 2014 Sep;64(3):465-71. doi: 10.1161/HYPERTENSIONAHA.114.03565. Epub 2014 Jun 9.

PMID:
24914189
9.

Trends in prevalence, awareness, treatment, and control of hypertension, and the risk of mortality among middle-aged Lithuanian urban population in 1983-2009.

Reklaitiene R, Tamosiunas A, Virviciute D, Baceviciene M, Luksiene D.

BMC Cardiovasc Disord. 2012 Aug 31;12:68. doi: 10.1186/1471-2261-12-68.

10.

Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008.

Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC.

Circulation. 2011 Aug 30;124(9):1046-58. doi: 10.1161/CIRCULATIONAHA.111.030189. Epub 2011 Aug 8.

11.

Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort.

Calhoun DA, Booth JN 3rd, Oparil S, Irvin MR, Shimbo D, Lackland DT, Howard G, Safford MM, Muntner P.

Hypertension. 2014 Mar;63(3):451-8. doi: 10.1161/HYPERTENSIONAHA.113.02026. Epub 2013 Dec 9.

12.
13.

Cardiovascular risk with and without antihypertensive drug treatment in the Japanese general population: participant-level meta-analysis.

Asayama K, Satoh M, Murakami Y, Ohkubo T, Nagasawa SY, Tsuji I, Nakayama T, Okayama A, Miura K, Imai Y, Ueshima H, Okamura T; Evidence for Cardiovascular Prevention From Observational Cohorts in Japan (EPOCH-JAPAN) Research Group.

Hypertension. 2014 Jun;63(6):1189-97. doi: 10.1161/HYPERTENSIONAHA.113.03206. Epub 2014 Mar 17.

PMID:
24637661
14.

Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease.

Bangalore S, Fayyad R, Laskey R, Demicco DA, Deedwania P, Kostis JB, Messerli FH; Treating to New Targets Steering Committee and Investigators.

Am J Med. 2014 Jan;127(1):71-81.e1. doi: 10.1016/j.amjmed.2013.07.038. Epub 2013 Nov 7.

PMID:
24210549
15.

Prehypertension and incident acute coronary heart disease in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study.

Glasser SP, Khodneva Y, Lackland DT, Prineas R, Safford MM.

Am J Hypertens. 2014 Feb;27(2):245-51. doi: 10.1093/ajh/hpt200. Epub 2013 Nov 4.

16.

Is pulse pressure an independent risk factor for incident acute coronary heart disease events? The REGARDS study.

Glasser SP, Halberg DL, Sands C, Gamboa CM, Muntner P, Safford M.

Am J Hypertens. 2014 Apr;27(4):555-63. doi: 10.1093/ajh/hpt168. Epub 2013 Sep 12.

PMID:
24029164
17.

Stroke and coronary heart disease in treated hypertension -- a prospective cohort study over three decades.

Almgren T, Persson B, Wilhelmsen L, Rosengren A, Andersson OK.

J Intern Med. 2005 Jun;257(6):496-502.

PMID:
15910553
18.

Prevalence of apparent treatment-resistant hypertension among individuals with CKD.

Tanner RM, Calhoun DA, Bell EK, Bowling CB, GutiƩrrez OM, Irvin MR, Lackland DT, Oparil S, Warnock D, Muntner P.

Clin J Am Soc Nephrol. 2013 Sep;8(9):1583-90. doi: 10.2215/CJN.00550113. Epub 2013 Jul 18.

19.

Relation of blood pressure components and categories and all-cause, stroke and coronary heart disease mortality in urban Chinese women: a population-based prospective study.

Dorjgochoo T, Shu XO, Zhang X, Li H, Yang G, Gao L, Cai H, Gao YT, Zheng W.

J Hypertens. 2009 Mar;27(3):468-75. doi: 10.1097/HJH.0b013e3283220eb9.

20.

Mortality implications of angina and blood pressure in hypertensive patients with coronary artery disease: New data from extended follow-up of the International Verapamil/Trandolapril Study (INVEST).

Winchester DE, Cooper-Dehoff RM, Gong Y, Handberg EM, Pepine CJ; INVEST Investigators.

Clin Cardiol. 2013 Aug;36(8):442-7. doi: 10.1002/clc.22145. Epub 2013 May 29.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk